Literature DB >> 23055876

Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.

Robert J Holt1, Scott W K Siegert, Aravind Krishna.   

Abstract

PURPOSE: To study the physical compatibility of ibuprofen lysine injection (NeoProfen, Ovation Pharmaceuticals Inc., Deerfield, IL) with medications commonly used in the premature neonatal population during simulated Y-site administration.
MATERIALS AND METHODS: Commonly used intravenous medications in preterm infants were evaluated for physical compatibility with ibuprofen lysine injection. A 20-mL sample of ibuprofen lysine drug product solution was mixed with a 20-mL sample of each of the 34 medications at concentrations used clinically. The mixtures were stored at room temperature and each sample was evaluated for turbidity and physical appearance at time 0 (immediately after preparation) and at 4 hours after preparation.
RESULTS: THE FOLLOWING DRUGS WERE DEEMED COMPATIBLE WITH IBUPROFEN LYSINE: ceftazidime, epinephrine, furosemide, heparin lock flush, diluted insulin, morphine sulfate, phenobarbital, potassium chloride, and sodium bicarbonate. Diluted dopamine was initially compatible at time 0 but showed a small precipitate at the 4-hour time point.
CONCLUSION: Of the 37 drug solutions tested, 14 preparations (10 medications; several with more than one diluent) showed physical compatibility with ibuprofen lysine, 1 was compatible at time 0 and incompatible at 4 hours, and 1 could not be evaluated. The remaining preparations were considered to be incompatible.

Entities:  

Keywords:  compatibility; ductus arteriosus; ibuprofen lysine

Year:  2008        PMID: 23055876      PMCID: PMC3462039          DOI: 10.5863/1551-6776-13.3.156

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  5 in total

1.  A preliminary report--heparin counteracts indomethacin effect on ductus arteriosus in very low birthweight infants.

Authors:  Tiina H Ojala; Liisa Lehtonen
Journal:  Pediatr Crit Care Med       Date:  2007-05       Impact factor: 3.624

2.  Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets.

Authors:  L V Allen; R S Levinson; D Phisutsinthop
Journal:  Am J Hosp Pharm       Date:  1977-09

3.  A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.

Authors:  B Van Overmeire; K Smets; D Lecoutere; H Van de Broek; J Weyler; K Degroote; J P Langhendries
Journal:  N Engl J Med       Date:  2000-09-07       Impact factor: 91.245

4.  Reported medication use in the neonatal intensive care unit: data from a large national data set.

Authors:  Reese H Clark; Barry T Bloom; Alan R Spitzer; Dale R Gerstmann
Journal:  Pediatrics       Date:  2006-06       Impact factor: 7.124

5.  Physical compatibility of neonatal total parenteral nutrient admixtures containing organic calcium and inorganic phosphate salts.

Authors:  Mansi J Parikh; Greg Dumas; Anthony Silvestri; Bruce R Bistrian; David F Driscoll
Journal:  Am J Health Syst Pharm       Date:  2005-06-01       Impact factor: 2.637

  5 in total
  2 in total

1.  Y-site compatibility of medications with parenteral nutrition.

Authors:  Christine A Robinson; Jaclyn E Sawyer
Journal:  J Pediatr Pharmacol Ther       Date:  2009-01

2.  Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion.

Authors:  Jowell Garcia; Alka Garg; Yunmei Song; Ambados Fotios; Chad Andersen; Sanjay Garg
Journal:  PLoS One       Date:  2018-01-03       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.